Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Up1.00% Nasdaq Up1.29%

Agios Pharmaceuticals, Inc. (AGIO)

39.21 Down 0.79(1.98%) 4:00PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
Agios Pharmaceuticals, Inc.
38 Sidney Street
2nd Floor
Cambridge, MA 02139
United States - Map
Phone: 617-649-8600

Index Membership:N/A
Full Time Employees:96

Business Summary 

Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its product candidates include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. The company is also developing AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology. Agios Pharmaceuticals, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Agios Pharmaceuticals, Inc.

Key Executives 
Dr. David P. Schenkein M.D., 57
Chief Exec. Officer and Director
Dr. Lewis Clayton Cantley Ph.D., 65
Co-Founder, Director, Member of Scientific Advisory Board and Member of Nominating & Corp. Governance Committee
Mr. Glenn Goddard , 43
Principal Financial Officer, Principal Accounting Officer and Sr. VP of Fin.
Mr. John Duncan Higgons M.Sc (Economics), 59
Chief Operating Officer
Dr. Scott Biller Ph.D., 58
Chief Scientific Officer
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders